Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.

The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.

The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.

The Canadian allowance expands Anixa's international intellectual property portfolio beyond existing U.S. protection. In July 2025, the company received U.S. Patent Number 12,357,593 covering similar vaccine technology aspects.

"This Canadian Notice of Allowance further strengthens the international patent protection around our ovarian cancer vaccine program and supports the novelty of our AMHR2-targeted immunoprevention approach," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.

The vaccine uses a "retired" protein strategy designed to train the immune system to recognize cells associated with ovarian cancer while avoiding damage to normal tissue. This approach was developed at Cleveland Clinic and exclusively licensed to Anixa.

Anixa also develops a breast cancer vaccine that completed Phase 1 clinical trials funded by a U.S. Department of Defense grant and conducted with Cleveland Clinic. The company reported all primary endpoints were met in that trial.